Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

ClinicalTrials.gov ID: NCT04093362

Public ClinicalTrials.gov record NCT04093362. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label, multinational, parallel 2-arm, randomized Phase 3 study evaluating the efficacy and safety of futibatinib versus gemcitabine-cisplatin chemotherapy as first-line treatment of participants with advanced, metastatic, or recurrent unresectable intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene rearrangements

Study identification

NCT ID: NCT04093362
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Taiho Oncology, Inc.; Industry
Enrollment: 10 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 6, 2021 (Actual)
Primary completion: Apr 22, 2024 (Actual)
Completion: Apr 22, 2024 (Actual)
Last update posted: Feb 7, 2025

2021 – 2024

United States locations

U.S. sites: 8
U.S. states: 7
U.S. cities: 8

Facility	City	State	ZIP	Site status
City of Hope National Medical Center	Duarte	California	91010	—
Norton Cancer Institute Audubon Hospital Campus Medical Plaza	Louisville	Kentucky	40217	—
New Mexico Cancer Care Alliance	Albuquerque	New Mexico	87131	—
Utah Cancer Specialists	Salt Lake City	Utah	84106	—
University of Virginia Cancer Center	Charlottesville	Virginia	22908	—
Medical Oncology Associates, PS - Summit Cancer Centers	Spokane	Washington	99208	—
Carbone Comprehensive Cancer Center	Madison	Wisconsin	53792	—
Medical College of Wisconsin - Froedtert Hospital	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 95 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04093362, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 7, 2025 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04093362 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →